Plasma Cabozantinib Level Measurement in Patients with Renal Cell and Hepatocellular Carcinomas Using a Simple HPLC–UV Method Suitable for Clinical Application
Abstract
:1. Introduction
2. Materials and Methods
2.1. Reagents and Chemicals
2.2. Equipment and Chromatographic Conditions
2.3. Preparation of Stock and Working Solutions
2.4. Sample Preparation
2.5. Calibration and Validation
2.6. Stability
2.7. Survey of Concomitant Medications in Patients Who Received Cabozantinib Using Real-World Data
2.8. Selectivity
2.9. Clinical Application
3. Results
3.1. Chromatography
3.2. Calibration and Validation
3.3. Stability
3.4. Survey of Concomitant Medications in Patients Who Received Cabozantinib Using Real-World Data
3.5. Selectivity
3.6. Clinical Application
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Yakes, F.M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.; et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer Ther. 2011, 10, 2298–2308. [Google Scholar] [CrossRef] [PubMed]
- Choueiri, T.K.; Escudier, B.; Powles, T.; Tannir, N.M.; Mainwaring, P.N.; Rini, B.I.; Hammers, H.J.; Donskov, F.; Roth, B.J.; Peltola, K.; et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016, 17, 917–927. [Google Scholar] [CrossRef] [PubMed]
- Abou-Alfa, G.K.; Meyer, T.; Cheng, A.L.; El-Khoueiry, A.B.; Rimassa, L.; Ryoo, B.Y.; Cicin, I.; Merle, P.; Chen, Y.; Park, J.W.; et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 2018, 379, 54–63. [Google Scholar] [CrossRef] [PubMed]
- Tomita, Y.; Tatsugami, K.; Nakaigawa, N.; Osawa, T.; Oya, M.; Kanayama, H.; Nakayama Kondoh, C.; Sassa, N.; Nishimura, K.; Nozawa, M.; et al. Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients. Int. J. Urol. 2020, 27, 952–959. [Google Scholar] [CrossRef] [PubMed]
- Kudo, M.; Tsuchiya, K.; Kato, N.; Hagihara, A.; Numata, K.; Aikata, H.; Inaba, Y.; Kondo, S.; Motomura, K.; Furuse, J.; et al. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: A phase 2 multicenter study. J. Gastroenterol. 2021, 56, 181–190. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, L.; Chapel, S.; Tran, B.D.; Lacy, S. Cabozantinib exposure-response analyses of efficacy and safety in patients with advanced hepatocellular carcinoma. J. Pharmacokinet. Pharmacodyn. 2019, 46, 577–589. [Google Scholar] [CrossRef] [PubMed]
- Nokihara, H.; Nishio, M.; Yamamoto, N.; Fujiwara, Y.; Horinouchi, H.; Kanda, S.; Horiike, A.; Ohyanagi, F.; Yanagitani, N.; Nguyen, L.; et al. Phase 1 study of cabozantinib in Japanese patients with expansion cohorts in non-small-cell lung cancer. Clin. Lung Cancer 2019, 20, e317–e328. [Google Scholar] [CrossRef] [PubMed]
- Okubo, H.; Ando, H.; Takasaki, Y.; Nakadera, E.; Fukuo, Y.; Shiina, S.; Ikejima, K. Impact of cabozantinib exposure on proteinuria and muscle toxicity in patients with unresectable hepatocellular carcinoma. Pharmaceuticals 2022, 15, 1460. [Google Scholar] [CrossRef] [PubMed]
- Cerbone, L.; Combarel, D.; Geraud, A.; Auclin, E.; Foulon, S.; Alves Costa Silva, C.; Colomba, E.; Carril, L.; Derosa, L.; Flippot, R.; et al. Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: Results from a pharmacokinetics/pharmacodynamics study. ESMO Open 2021, 6, 100312. [Google Scholar] [CrossRef] [PubMed]
- Ferrer, F.; Solas, C.; Giocanti, M.; Lacarelle, B.; Deville, J.L.; Gravis, G.; Ciccolini, J. A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: Application to therapeutic drug monitoring in patients with renal cell carcinoma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2020, 1138, 121968. [Google Scholar] [CrossRef] [PubMed]
- Maruyama, S.; Kato, M.; Hiraga, T.; Ishida, M.; Kanno, H. Quantitative determination of plasma cabozantinib concentration using HPLC-UV and its application to patients with renal cell carcinoma. Biomed Chromatogr. 2023, 37, e5599. [Google Scholar] [CrossRef] [PubMed]
- Koeber, R.; Kluenemann, H.H.; Waimer, R.; Koestlbacher, A.; Wittmann, M.; Brandl, R.; Doerfelt, A.; Jahner, T.; Melchner, D.; Haen, E. Implementation of a cost-effective HPLC/UV-approach for medical routine quantification of donepezil in human serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012, 881–882, 1–11. [Google Scholar] [CrossRef] [PubMed]
- United States Food and Drug Administration, Center for Drug Evaluation and Research (CDER), & Center for Veterinary Medicine. Guidance for Industry, Bioanalytical Method Validation; CMV: Silver Spring, MD, USA, 2018. [Google Scholar]
- Lacy, S.A.; Miles, D.R.; Nguyen, L.T. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin. Pharmacokinet. 2017, 56, 477–491. [Google Scholar] [CrossRef] [PubMed]
- Krens, S.D.; van Erp, N.P.; Groenland, S.L.; Moes, D.J.A.R.; Mulder, S.F.; Desar, I.M.E.; van der Hulle, T.; Steeghs, N.; van Herpen, C.M.L. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. BMC Cancer 2022, 22, 228. [Google Scholar] [CrossRef] [PubMed]
- Mueller-Schoell, A.; Groenland, S.L.; Scherf-Clavel, O.; van Dyk, M.; Huisinga, W.; Michelet, R.; Jaehde, U.; Steeghs, N.; Huitema, A.D.R.; Kloft, C. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur. J. Clin. Pharmacol. 2021, 77, 441–464. [Google Scholar] [CrossRef] [PubMed]
- Rassy, E.; Cerbone, L.; Auclin, E.; Benchimoll-Zouari, A.; Flippot, R.; Alves Costa Silva, C.; Colomba, E.; Geraud, A.; Guida, A.; Mir, O.; et al. The effect of concomitant proton pump inhibitor and cabozantinib on the outcomes of patients with metastatic renal cell carcinoma. Oncologist 2021, 26, 389–396. [Google Scholar] [CrossRef] [PubMed]
- Buti, S.; Tommasi, C.; Scartabellati, G.; De Giorgi, U.; Brighi, N.; Rebuzzi, S.E.; Puglisi, S.; Caffo, O.; Kinspergher, S.; Mennitto, A.; et al. The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Anticancer Drugs 2023, 34, 178–186. [Google Scholar] [CrossRef]
- Amaro, F.; Carvalho, M.; Bastos, M.L.; Guedes de Pinho, P.; Pinto, J. Pharmacometabolomics applied to personalized medicine in urological cancers. Pharmaceuticals 2022, 15, 295. [Google Scholar] [CrossRef] [PubMed]
- Sharma, R.; Kadife, E.; Myers, M.; Kannourakis, G.; Prithviraj, P.; Ahmed, N. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. J. Exp. Clin. Cancer Res. 2021, 40, 186. [Google Scholar] [CrossRef] [PubMed]
- di Meo, N.A.; Lasorsa, F.; Rutigliano, M.; Loizzo, D.; Ferro, M.; Stella, A.; Bizzoca, C.; Vincenti, L.; Pandolfo, S.D.; Autorino, R.; et al. Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets. Int. J. Mol. Sci. 2022, 23, 14360. [Google Scholar] [CrossRef] [PubMed]
Intraday (n = 5) | Interday (n = 5) | ||||||
---|---|---|---|---|---|---|---|
Theoretical Cabozantinib Concentration (µg/mL) | Detected (µg/mL) Mean ± SD | CV (%) | Accuracy (%) | Detected (µg/mL) Mean ± SD | CV (%) | Accuracy (%) | Recovery (%) |
0.05 | 0.05 ± 0.002 | 3.26 | 0.79 | 0.05 ± 0.000 | 2.00 | −1.05 | 96.04 |
0.1 | 0.10 ± 0.002 | 2.17 | −1.36 | 0.10 ± 0.003 | 2.52 | 0.98 | 99.44 |
0.5 | 0.49 ± 0.010 | 1.97 | −1.57 | 0.50 ± 0.005 | 1.01 | 0.94 | 103.00 |
1.0 | 0.97 ± 0.008 | 0.81 | −3.39 | 1.00 ± 0.013 | 1.32 | −0.19 | 101.49 |
2.5 | 2.42 ± 0.018 | 0.70 | −3.17 | 2.50 ± 0.033 | 1.33 | −0.15 | 103.70 |
5.0 | 4.78 ± 0.040 | 0.84 | −4.35 | 4.98 ± 0.090 | 1.80 | −0.38 | 104.52 |
Stability Condition (%) | ||||
---|---|---|---|---|
Theoretical Cabozantinib Concentration (µg/mL) | Benchtop Mean ± SD | Short-Term 24 h Mean ± SD | Long-Term 1 month Mean ± SD | Freeze and Thaw Mean ± SD |
0.05 | 92.77 ± 1.456 | 112.35 ± 3.009 | 101.74 ± 2.139 | 100.50 ± 3.412 |
1.0 | 100.81 ± 1.329 | 97.85 ± 2.013 | 97.53 ± 1.490 | 98.99 ± 0.516 |
5.0 | 97.51 ± 1.043 | 97.65 ± 1.648 | 95.28 ± 1.436 | 100.30 ± 2.056 |
Medication | n = 374 (%) |
---|---|
Levothyroxine sodium | 161 (43) |
Amlodipine besilate | 141 (38) |
Ursodeoxycholic acid | 88 (24) |
Acetaminophen | 87 (23) |
Magnesium oxide | 73 (20) |
Vonoprazan fumarate | 70 (19) |
Esomeprazole magnesium | 67 (18) |
Furosemide | 64 (17) |
Febuxostat | 60 (16) |
Nifedipine | 58 (16) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yasu, T.; Gando, Y.; Nishijima, R.; Ikuta, R.; Suzuki, M.; Shirota, M. Plasma Cabozantinib Level Measurement in Patients with Renal Cell and Hepatocellular Carcinomas Using a Simple HPLC–UV Method Suitable for Clinical Application. Curr. Oncol. 2023, 30, 4871-4879. https://doi.org/10.3390/curroncol30050367
Yasu T, Gando Y, Nishijima R, Ikuta R, Suzuki M, Shirota M. Plasma Cabozantinib Level Measurement in Patients with Renal Cell and Hepatocellular Carcinomas Using a Simple HPLC–UV Method Suitable for Clinical Application. Current Oncology. 2023; 30(5):4871-4879. https://doi.org/10.3390/curroncol30050367
Chicago/Turabian StyleYasu, Takeo, Yoshito Gando, Ryosuke Nishijima, Risa Ikuta, Motofumi Suzuki, and Mikio Shirota. 2023. "Plasma Cabozantinib Level Measurement in Patients with Renal Cell and Hepatocellular Carcinomas Using a Simple HPLC–UV Method Suitable for Clinical Application" Current Oncology 30, no. 5: 4871-4879. https://doi.org/10.3390/curroncol30050367
APA StyleYasu, T., Gando, Y., Nishijima, R., Ikuta, R., Suzuki, M., & Shirota, M. (2023). Plasma Cabozantinib Level Measurement in Patients with Renal Cell and Hepatocellular Carcinomas Using a Simple HPLC–UV Method Suitable for Clinical Application. Current Oncology, 30(5), 4871-4879. https://doi.org/10.3390/curroncol30050367